




# Securing medication circuit in oncology pediatriy units in French speaking Africa. MAEva pilot program results.



MAEVA

Line Couitchere<sup>1,2</sup>, Innocent Krasse <sup>2,3</sup>, Léa Zaho<sup>1,2</sup>, Marina Yao<sup>2,4</sup>, Guy Yao<sup>1,2</sup>, Olga Molly<sup>1,2</sup>, Max N'Doumy<sup>1,2</sup>, Charles Akoun<sup>1,2</sup>, Magloire Amichia<sup>4</sup>, Bertrand Pourroy<sup>2,5</sup>

- <sup>1</sup> Pediatrics Oncology Unit, University Teaching Hospital of Treichville, Abidjan, Côte d'Ivoire  
<sup>2</sup> Groupe Francophone Africain d'Oncologie Pédiatrique (GFAOP), Villejuif, France  
<sup>3</sup>Programme National de Lutte contre le Cancer (PNLCa-CI), Abidjan, Côte d'Ivoire  
<sup>4</sup> Pharmacy Department, University Teaching Hospital of Treichville, Abidjan, Côte d'Ivoire  
<sup>5</sup> Assistance Publique-Hôpitaux de Marseille, Marseille, France



## 1



### INTRODUCTION

Securing the drug circuit is a key point in the care of children with cancer. A failure in the circuit, whether it occurs at the medical (prescription), pharmaceutical (dispensing) or nursing (administration) stage, can result in serious damage for children but also additional costs for families (prolonged hospitalizations) or society (loss of rare resources such as medicines). We developed, supported by the **PRPH3** (Projet Réseaux et Partenariats Hospitaliers), a pilot study in Côte d'Ivoire in order to secure it.

## 3

### RESULTS

- Two pediatricians, 1 pharmacist and 2 nurses were questioned.
- **In June 2022,**
    - Risk levels were 32%, 33% and 42% for pediatricians, pharmacist and nurses, respectively (see Figure A).
    - A 13 actions plan was built (see Figure B).
  - **In September 2023,**
    - Five actions were completed, 6 were initiated and 3 still pending (see figure A).
    - Global level of action plan implementation was 54%. (see Figure C)
    - Risk levels were 14%, 23% and 34% for pediatricians, pharmacist, and nurses, respectively (see Figure A).




## 2

### METHODS

A multidisciplinary team was built to adapt to the African context a previously created tool **(1)**. This new tool, so called **MAEva (Medication Africa Evaluation)**, consists in 3 questionnaires. These ones allow to define, through basic questions to care professionals (dichotomic answers yes/no) a global risk level expressed in percentage for each sub-level of medication process (prescription, dispensing and administration). A sample of audit result is shown below

A baseline evaluation was done in June 2022 and, according to results, an action plan was built. In September 2023, a second evaluation was done. Level of risks, number of actions completed and percentage of completion of action plan were used to evaluate MAEva use impact.



## 4

### DISCUSSION

This pilot study showed that a simple evaluating tool may identify medication circuit dysfunctions and allow to correct them. According to these very encouraging results, the African Francophone Group for Oncology Pediatrics (GFAOP) launched, supported by Foundation S, in 2023 October, the MAEva program which will transpose this methodology in 6 other oncology pediatrics units.

